Document Detail


Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure.
MedLine Citation:
PMID:  22737998     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Objective: To evaluate the short-term impact of intravitreal ranibizumab injection on axial ocular dimension (AOD) and intraocular pressure (IOP). Methods: A total of 31 patients who received 0.05 mL intravitreal ranibizumab injection (IRI) for age-related macular degeneration and 30 healthy volunteers were enrolled in the study. AODs i.e. anterior chamber depth and axial length were measured with IOL Master and IOP with noncontact tonometer before and 5 min, 30 min and 1 day after the injection. Results: Five minutes after the injection, mean IOP increased to 24.8 ± 9.5 (13-46) mmHg from 14.5 ± 2.3 (10-18) mmHg (p < 0.001). Thirty minutes after the injection, IOP decreased a mean level of 17.3 ± 4.1 (11-26) mmHg. The change in axial length and anterior chamber depth measurements did not reach a statistical significance across the time points (p > 0.05, for all values). There was no correlation between biometric measurements and IOP before (r = 0.016, p = 0.948 for axial length and r = -0.48 p = 0.075 for anterior chamber depth) and 5 min after IRI (r = 0.049, p = 0.835 for axial length and r = -0.219 p = 0.367 for anterior chamber depth). Measurements of control group taken across same time points did not reveal statistically significant differences (p > 0.05, for all measurements). Conclusion: Although IOP increases transiently after the intravitreal injection of 0.05 mL ranibizumab, axial length and anterior chamber depth are not affected by this amount of injection, and the increase in IOP after the injection seems to be irrelevant to AL and anterior chamber depth. Therefore, it is postulated that ranibizumab can be used safely in patients with age-related macular degeneration who have shallow anterior chamber and/or short axial length simultaneously.
Authors:
Altan Goktas; Sertan Goktas; Mustafa Atas; Suleyman Demircan; Yusufcan Yurtsever
Related Documents :
19566818 - Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy...
19320558 - Exenatide improves hypertension in a rat model of the metabolic syndrome.
1071648 - Importance of hypertension and genetic factors for atherogenesis in rats.
16543658 - Investigation of beat-to-beat cardiovascular activity of rats by radio telemetry.
20479968 - Angiotensin-i-converting enzyme (ace) inhibitors from marine resources: prospects in th...
17070608 - Acute severe midventricular obstruction in left ventricular apical ballooning syndrome.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-27
Journal Detail:
Title:  Cutaneous and ocular toxicology     Volume:  -     ISSN:  1556-9535     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101266892     Medline TA:  Cutan Ocul Toxicol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Ophthalmology, Training and Research Hospital , Kayseri , Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fingolimod Reduces Direct Medical Costs Compared to Natalizumab in Patients with Relapsing-Remitting...
Next Document:  Baylor SBIRT Medical Residency Training Program: Model Description and Initial Evaluation.